Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
New research exposes how prompt injection in AI agent frameworks can lead to remote code execution. Learn how these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results